Abivax, buoyed by HIV milestone, leads surge in value of biotech stocks in Paris


Abivax's share price has surged more than 160% in a little more than one trading session. Investors drove up the stock on the back of news regarding its HIV collaboration, sparking a chain of events that saw the share prices of a clutch of biotech stocks surge on the Paris exchange.

Paris-based Abivax (EPA:ABVX) experienced the most dramatic rise, gaining 87% one day and continuing the rapid upswing the next morning. The surge followed an update on the Abivax-led Project CaReNa, a Bpifrance-backed scheme that pairs the French biotech with Theradiag and the French National Center for Scientific Research to develop HIV drugs and diagnostics targeting protein-RNA interactions.

As a result of progress with ABX464, an HIV antiviral, Project CaReNa has now completed its second key milestone, news that was disclosed in a statement this week. The drug is yet to advance beyond Phase II--a Phase IIa trial to assess the long-term effect of ABX464 on viral load is due to report early data later this year--but, with Abivax’s share price depressed by a setback to its hepatitis B vaccine, the news was enough to send its stock on a two-day tear.

The jump, which moved Abivax’s share price up to levels last seen before the hepatitis B blow, was the most meteoric rise on a busy period for traders in Paris. Biophytis (EPA:ALBPS) rose 35% in early trading on Thursday, despite its most recent statement--a trial start update that failed to move the stock--being published 48 hours earlier. Shares in TxCell (EPA:TXCL) spiked more than 10% before falling back toward earth. Sensorion (EPA:ALSEN) and Genticel (EPA:GTCL) both rose, too.

Each of the biotechs has a small market cap--Abivax leads the pack at €97 million ($109 million)--and on a typical day is traded in relatively small volumes. For a short window on Thursday, those volumes increased sharply, as did the share prices and market caps of the companies caught up in the trading frenzy.

Suggested Articles

Bristol Myers Squibb and bluebird bio filed their BCMA-targeting CAR-T therapy for FDA approval, teeing it up for a potential green light in 2020.

Smith+Nephew is contracting with the U.K. government to build a new ventilator specifically designed for large-scale production.

NantWorks’ ImmunityBio has begun a supercomputing collaboration with Microsoft to map out the spike protein of the novel coronavirus.